Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis (Q38195521)

30 August 2017

1 reference

title

Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis (English)

1 reference

30 August 2017

0 references

2

Emma D Deeks

1 reference

30 August 2017

Celeste B Burness

1

1 reference

30 August 2017

publication date

1 April 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

28

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

373-387

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

30 August 2017

1 reference

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Oxidative damage in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Effects of dimethyl fumarate on neuroprotection and immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

BG-12 in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0155-5

PML in a patient treated with fumaric acid

21 January 2018

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

1 reference

12 December 2020

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

1 reference

12 December 2020

Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

10.1007/S40263-014-0155-5

Identifiers

DOI

1 reference

30 August 2017

1 reference